Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Technology Applications: Use of Digital Health Technology to Enable Drug Development

Technology Applications: Use of Digital Health Technology to Enable Drug Development Purpose: This pilot study developed and evaluated the feasibility, usability, and perceived satisfaction with an end-user mobile medical application and provider web portal. The two interfaces allowed for remote monitoring, provided daily guidance in the management of hypertension and diarrhea, and allowed for rapid management of adverse events during a clinical trial of olaparib and cediranib. Patients and Methods: eCO (eCediranib/Olaparib) was designed for patient self-reported, real-time management of hypertension and diarrhea using remote monitoring. eCO links to a Bluetooth-enabled blood pressure (BP) monitor and transmits data to a secure provider web portal. eCO use was assessed for suitability, usability, and satisfaction after 4 weeks using a 17-item questionnaire. Metrics regarding patient-reported BP and diarrhea events were analyzed. Results: Sixteen patients enrolled in the pilot. A total of 98.2% of expected BP values were reported: 94.2% via Bluetooth and 5.8% entered manually. Twelve patients experienced 21 BP events (systolic BP > 140 and/or diastolic BP > 90 mmHg on two consecutive readings); data from cycle 1 were comparable to the study database. Thirteen patients reported diarrhea (more than one stool per 24 hours over baseline) categorized as grade 1 or 2, which was comparable to the study database. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their health care team. The only aspect of the application that did not show a statistically significant positive response was the process of reporting diarrhea. Conclusion: The eCO application was designed to assist in managing acute treatment-related events most often associated with treatment discontinuation, need for drug holidays, or dose interruption. Hypertension and diarrhea events reported via eCO allowed rapid provider response and a positive overall patient experience. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO Clinical Cancer Informatics Wolters Kluwer Health

Technology Applications: Use of Digital Health Technology to Enable Drug Development

Download PDF
12 pages

Loading next page...
 
/lp/wolters-kluwer-health/technology-applications-use-of-digital-health-technology-to-enable-XQuwXs6uzN
Publisher
Wolters Kluwer Health
Copyright
(C) 2018 by Lippincott Williams & Wilkins, Inc.
ISSN
2473-4276
DOI
10.1200/CCI.17.00153
Publisher site
See Article on Publisher Site

Abstract

Purpose: This pilot study developed and evaluated the feasibility, usability, and perceived satisfaction with an end-user mobile medical application and provider web portal. The two interfaces allowed for remote monitoring, provided daily guidance in the management of hypertension and diarrhea, and allowed for rapid management of adverse events during a clinical trial of olaparib and cediranib. Patients and Methods: eCO (eCediranib/Olaparib) was designed for patient self-reported, real-time management of hypertension and diarrhea using remote monitoring. eCO links to a Bluetooth-enabled blood pressure (BP) monitor and transmits data to a secure provider web portal. eCO use was assessed for suitability, usability, and satisfaction after 4 weeks using a 17-item questionnaire. Metrics regarding patient-reported BP and diarrhea events were analyzed. Results: Sixteen patients enrolled in the pilot. A total of 98.2% of expected BP values were reported: 94.2% via Bluetooth and 5.8% entered manually. Twelve patients experienced 21 BP events (systolic BP > 140 and/or diastolic BP > 90 mmHg on two consecutive readings); data from cycle 1 were comparable to the study database. Thirteen patients reported diarrhea (more than one stool per 24 hours over baseline) categorized as grade 1 or 2, which was comparable to the study database. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their health care team. The only aspect of the application that did not show a statistically significant positive response was the process of reporting diarrhea. Conclusion: The eCO application was designed to assist in managing acute treatment-related events most often associated with treatment discontinuation, need for drug holidays, or dose interruption. Hypertension and diarrhea events reported via eCO allowed rapid provider response and a positive overall patient experience.

Journal

JCO Clinical Cancer Informatics – Wolters Kluwer Health

Published: Jun 29, 2018

Keywords: FLT1

References

  • Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    Matulonis UA; Berlin S; Ivy P
  • Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
    Ivy SP; Liu JF; Lee J-M
  • Initial toxicity assessment of ICON6: A randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
    Raja FA; Griffin CL; Qian W
  • Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial
    Ledermann JA; Embleton AC; Raja F
  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study
    Liu JF; Barry WT; Birrer M
  • A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
    Liu JF; Tolaney SM; Birrer M
  • A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia
    Hirte H; Lheureux S; Fleming GF
  • Guidance on mobile medical applications
    US Food and Drug Administration
  • SUS: A "quick and dirty" usability scale, in Jordan PW, Thomas B, Weerdmeester BA, et al (eds): Usability Evaluation in Industry
    Brooke J
  • A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma
    Sridhar SS; Mackenzie MJ; Hotte SJ
  • Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
    Mulders P; Hawkins R; Nathan P
  • Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509
    Garland LL; Chansky K; Wozniak AJ
  • Application of mobile phone technology for managing chemotherapy-associated side-effects
    Weaver A; Young AM; Rowntree J
  • Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity
    Kearney N; McCann L; Norrie J
  • The development of a side effect risk assessment tool (ASyMS(C)-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy
    Maguire R
  • Patients' perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity
    McCann L; Maguire R; Miller M
  • Automated symptom alerts reduce postoperative symptom severity after cancer surgery: A randomized controlled clinical trial
    Cleeland CS; Wang XS; Shi Q
  • What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care
    Kotronoulas G; Kearney N; Maguire R
  • Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial
    Basch E; Deal AM; Kris MG
  • Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment
    Basch E; Deal AM; Dueck AC
  • Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients
    Denis F; Lethrosne C; Pourel N
  • Effect of telecare management on pain and depression in patients with cancer: A randomized trial
    Kroenke K; Theobald D; Wu J
  • Automated monitoring of symptoms during ambulatory chemotherapy and oncology providers' use of the information: A randomized controlled clinical trial
    Mooney KH; Beck SL; Friedman RH
  • Automated home monitoring and management of patient-reported symptoms during chemotherapy: Results of the symptom care at home RCT
    Mooney KH; Beck SL; Wong B
  • Improving outcomes in cancer patients on oral anti-cancer medications using a novel mobile phone-based intervention: Study design of a randomized controlled trial
    Agboola S; Flanagan C; Searl M
  • Mobile application to promote adherence to oral chemotherapy and symptom management: A protocol for design and development
    Fishbein JN; Nisotel LE; MacDonald JJ
  • Disruptive Dozen
    World Medical Innovation Forum